Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced positive results today from the pedia...
OnKai, a US-based technology company, combines public healthcare and medical innovation experience with complex process digitalization, design thinking, an...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients...
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...
EG1206A is a biosimilar drug of the second-generation HER2-positive antibody drug Perjeta® (pertuzumab). EG1206A has a unique binding mechanism for HER...
ASC40 is an oral, selective small molecule inhibitor of FASN. Mechanisms of ASC40 for acne are (1) direct inhibition of facial sebum production, through in...
The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, randomized, masked, controlled IDE clinical study...
There is growing recognition that the experimental model systems used in many cancer research projects, which include 2D cell cultures, patient-derived xen...
Aquavit will begin its Phase II/Phase III trials for DTX-023 (aqubotulinumtoxinA) and DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the...
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need T...
Tempest will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Friday, April 28th. To join the conference call via phone and pa...
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose,...
The recommendation is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete r...
The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort...
© 2024 Biopharma Boardroom. All Rights Reserved.
